LONDON, Oct 22 (Reuters) - British pharmaceutical companyGlaxoSmithKline will profile its drug developmentpipeline, including a new class of antibiotic, on Nov. 3, itschief executive said on Thursday.
The event in New York - the company's first investor daycentred on drug development for more than a decade - willprofile medicines from a pipeline that is 80 percentfirst-in-class, Andrew Witty said in a public interview at theChatham House think-tank in London.
It will include an update on its Type 2 topoisomeraseinhibitor drug candidate, which is in the Phase II stage ofdevelopment, according to Witty.
He said that only two new classes of antibiotics - drugswhich treat bacterial infections - had been discovered in thepast 40 years. "We have a third one," he said.
(Reporting by Paul Sandle; Editing by Mark Heinrich)
Glaxosmithkline (GSK)